Scholarlink

<p>The rapid rise in antibiotic resistance is making infections, particularly those caused by ESBL-positive and biofilm-forming <i>Escherichia coli</i> isolates, increasingly difficult to treat. Therefore, interest in alternative biotherapeutic approaches based on probiotic or postbiotic sources is increasing. Although there are many reports on the antibacterial and antibiofilm effects of probiotics in the current literature, the efficacy of <i>Lactobacillus salivarius</i> supernatant (LS-S) on ESBL-positive and biofilm-forming clinical <i>E. coli</i> isolates has not been studied sufficiently. The aim of this study was to evaluate the antibacterial and antibiofilm effects of LS-S against ESBL-positive <i>E. coli</i> isolates in vitro and to compare it with other probiotic-derived findings in the literature. Antibacterial activity was determined by modified disk diffusion and agar well diffusion methods, and growth inhibition was assessed over time using a microplate assay. Biofilm inhibition was measured using a quantitative biofilm assay, and the results were analyzed statistically. LS-S produced average inhibition zones of 16.0 ± 3.9&#xa0;mm (disk) and 18.8 ± 3.3&#xa0;mm (well) in ESBL-positive <i>E. coli</i> isolates. Microplate assay results showed that inhibition reached 20% at 3&#xa0;h, 65–70% at 6–12&#xa0;h, and 87% at 24&#xa0;h. In biofilm analyses, biofilm formation was suppressed in all isolates, with inhibition exceeding 40% detected in 13 isolates (43.3%), and the highest efficacy was found to be 73.1%. The data obtained demonstrate that LS-S has the capacity to inhibit both planktonic growth and biofilm development. These findings demonstrate that postbiotic-based biotherapeutics are promising candidates for infection control in the era of antibiotic resistance and highlight the need for in vivo and translational studies for clinical applications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Postbiotic approach to antibiotic resistance: antibacterial and antibiofilm potential of Lactobacillus salivarius supernatant

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月10日

查看全文
  • E. Akgol,
  • Elif Aydin,
  • A. Temel,
  • Percin Renders D.

摘要

The rapid rise in antibiotic resistance is making infections, particularly those caused by ESBL-positive and biofilm-forming Escherichia coli isolates, increasingly difficult to treat. Therefore, interest in alternative biotherapeutic approaches based on probiotic or postbiotic sources is increasing. Although there are many reports on the antibacterial and antibiofilm effects of probiotics in the current literature, the efficacy of Lactobacillus salivarius supernatant (LS-S) on ESBL-positive and biofilm-forming clinical E. coli isolates has not been studied sufficiently. The aim of this study was to evaluate the antibacterial and antibiofilm effects of LS-S against ESBL-positive E. coli isolates in vitro and to compare it with other probiotic-derived findings in the literature. Antibacterial activity was determined by modified disk diffusion and agar well diffusion methods, and growth inhibition was assessed over time using a microplate assay. Biofilm inhibition was measured using a quantitative biofilm assay, and the results were analyzed statistically. LS-S produced average inhibition zones of 16.0 ± 3.9 mm (disk) and 18.8 ± 3.3 mm (well) in ESBL-positive E. coli isolates. Microplate assay results showed that inhibition reached 20% at 3 h, 65–70% at 6–12 h, and 87% at 24 h. In biofilm analyses, biofilm formation was suppressed in all isolates, with inhibition exceeding 40% detected in 13 isolates (43.3%), and the highest efficacy was found to be 73.1%. The data obtained demonstrate that LS-S has the capacity to inhibit both planktonic growth and biofilm development. These findings demonstrate that postbiotic-based biotherapeutics are promising candidates for infection control in the era of antibiotic resistance and highlight the need for in vivo and translational studies for clinical applications.